

strategic relationships and dependence on key individuals. Products developed by the Company require clearances from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance the Company's product candidates will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or it is unable to maintain clearance, it could have a materially adverse impact on the Company.

3. Fair Value Measurements The Company's financial assets consist of money market funds, U.S. government debt securities and corporate debt securities. The following tables show the Company's cash equivalents and available-for-sale securities carrying amounts and fair values as of September 30, 2024, and December 31, 2023.

As of September 30, 2024, the Company's cash equivalents and available-for-sale securities carrying amounts and fair values are as follows:

Category	Carrying Amount	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
QuotedPricedInActiveMarkets(Level 1)	\$48,709	\$48,709	\$48,709	\$48,709
SignificantOtherObservableInputs(Level 2)	\$37,694	\$37,694	\$37,694	\$37,694
SignificantUnobservableInputs(Level 3)	\$120,670	\$120,670	\$120,670	\$120,670
Financial assets	\$197,435	\$401	\$197,836	\$121,011
Total financial assets	\$197,435	\$401	\$197,836	\$121,011

As of December 31, 2023, the Company's cash equivalents and available-for-sale securities carrying amounts and fair values are as follows:

Category	Carrying Amount	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
QuotedPricedInActiveMarkets(Level 1)	\$37,694	\$37,694	\$37,694	\$37,694
SignificantOtherObservableInputs(Level 2)	\$120,813	\$120,813	\$120,813	\$120,813
SignificantUnobservableInputs(Level 3)	\$228,359	\$191	\$228,550	\$135,568
Financial assets	\$228,359	\$191	\$228,550	\$135,568
Total financial assets	\$228,359	\$191	\$228,550	\$135,568

The Company had aggregate cash and cash equivalents of \$48,810, including cash equivalents of \$48,709, consisting of money market funds. As of December 31, 2023, the Company had aggregate cash and cash equivalents of \$37,706, including cash equivalents of \$37,694, consisting of money market funds. Money market funds are classified within level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.

7 PMV Pharmaceuticals, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) (in thousands, except share and per share amounts)

Marketable Securities: Marketable securities of \$149,127 as of September 30, 2024, consisted of corporate debt securities of \$36,399 and government debt securities of \$112,728. There were \$134,031 current marketable securities and \$15,096 noncurrent marketable securities as of September 30, 2024. Marketable securities of \$190,856 as of December 31, 2023, consisted of corporate debt securities of \$70,043 and government debt securities of \$120,813. There were \$165,351 current marketable securities and \$25,505 noncurrent marketable securities as of December 31, 2023.

As of September 30, 2024, and December 31, 2023, aggregated gross unrealized losses of available-for-sale investments were not material, and accordingly, no allowance for credit losses was recorded.

4. Property and Equipment, Net: As of September 30, 2024, and December 31, 2023, Machinery & equipment was \$2,730 and \$3,089. Computers, furniture & fixtures, leasehold improvements, and leasehold improvements were \$11,364 and \$10,765. Total property and equipment was \$14,176 and \$13,936. Less: Accumulated depreciation was \$4,046 and \$3,270. Property and equipment, net was \$10,130 and \$10,666. Depreciation expense for the three months ended September 30, 2024 and 2023 was \$371 and \$358, respectively. Depreciation expense for the nine months ended September 30, 2024 and 2023 was \$1,105 and \$898, respectively.

5. Accrued Expenses: Accrued expenses consist of the following:

Category	September 30, 2024	December 31, 2023
Accrued compensation	\$3,999	\$4,498
Accrued legal and professional services	\$343	\$172
Accrued research and development costs	\$5,915	\$5,270
Total	\$10,257	\$9,940

6. Commitments and Contingencies: Operating Leases: In August 2018, the Company executed two noncancelable operating leases. One lease for approximately 6,000 square feet for vivarium, laboratory and general office space in South Brunswick, New Jersey. The lease was set to expire in July 2022. In January 2022, the Company signed a lease extension for up to one additional year through July 2023, with the option to terminate upon 120 days of written notice, with an increase in base rent as per the lease extension. The lease was terminated as of June 2023. The second lease is for office space in Lexington, Massachusetts, that terminated in August 2023. In January 2021, the Company signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey. That lease term extends through 2032, has a five-year extension option, and replaced the Company's two existing facilities as the Company's headquarters in March 2023. Payment under this lease will total \$19,889 through May 2032. The Company received a lease incentive of \$4,046 from the lessor for a buildout of laboratory, vivarium, and office space. Management estimated the timing and amounts of reimbursements and included them as a reduction of lease payments when initially measuring the lease liability and right-of-use asset upon commencement. Since the inception date of the lease, \$4,046 reimbursements were received. For the nine months ended September 30, 2024, \$242 of reimbursements were received.

7 PMV Pharmaceuticals, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) (in thousands, except share and per share amounts)

In August 2024, the Company entered into a Lease Termination Agreement with BMR-One Research Way LLC, a Delaware limited liability company (the "Landlord"), in connection with the termination of the lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey (the "Termination Agreement"). Pursuant to the Termination Agreement, the Company and the Landlord agreed to terminate the lease at One Research Way in Princeton, New Jersey, contingent on the sale of the property by the Landlord to a prospective new buyer (the "Contingency"). The Contingency was met on the date of sale on October 1, 2024, and the lease was terminated on such date. Pursuant to the Termination Agreement, and subject to the Contingency, the Company agreed to surrender the property and paid a total termination fee of approximately \$1,420, consisting of (i) a cash payment in the amount of approximately \$798 and (ii) a release of a security deposit from the Company's existing letter of credit in the amount of approximately \$622. In September 2024, the Company signed a sublease agreement for 3,205 square feet of office and laboratory space at 311 Pennington Rocky Hill Road in Hopewell, New Jersey. The Company will utilize the premises as laboratory space for operational research and development activities. The sublease term extends through 2029 and provides the Company with the option to extend the term for an additional three year period. Payment under this sublease will total \$768 through December 2029. The components of lease cost for the three and nine months ended September 30, 2024 and 2023, are as follows:

Category	September 30, 2024	September 30, 2023
Operating lease cost	\$367	\$366
Variable lease cost	\$1,105	\$1,559
Less: Amounts reported in the balance sheet for leases where the Company is the lessee as of September 30, 2024, and December 31, 2023, as follows:	\$527	\$527
Operating Leases (in thousands, except lease term and discount rate data)	\$1,612	\$2,351
Right-of-use assets, operating leases	\$8,407	\$8,382
Operating lease liabilities, current	\$1,243	\$852
Operating lease liabilities, non-current	\$12,024	\$12,434
Total operating lease liabilities	\$13,267	\$13,286
Weighted-average remaining lease term (years)	7.57	8.42
Weighted-average discount rate	6.08%	5.75%
Other information related to leases for the nine months ended September 30, 2024 and 2023, respectively, as follows:		
Nine Months Ended September 30, (in thousands)	\$1,119	\$1,842
Leased assets obtained in exchange for new or modified operating lease liabilities	\$11	9

PMV Pharmaceuticals, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) (in thousands, except share and per share amounts)

Future minimum lease payments, net of reimbursements, remaining as of September 30, 2024, under operating leases by fiscal year were as follows:

Fiscal Year	2024	2025	2026	2027	2028	2029	2030	2031	2032
Operating lease cost	\$479	\$479	\$2,012	\$2,071	\$2,132	\$2,194	\$2,194	\$2,194	\$2,194
Less: Amounts representing imputed interest	\$3229	\$3229	\$13,267	\$13,267	\$13,267	\$13,267	\$13,267	\$13,267	\$13,267
Present value of lease liabilities	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496
Total minimum lease payments	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496	\$16,496

Less: Amounts representing imputed interest

Present value of lease liabilities

Total minimum lease payments

7. Stockholders' Equity: The Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of \$0.00001 per share and 5,000,000 shares of preferred stock with a par value of \$0.00001 per share. At September 30, 2024 and December 31, 2023, there were 51,749,504 and 51,445,862 shares of common stock issued and outstanding, respectively. Common stockholders are entitled to receive dividends if and when declared by the board of directors subject to the rights of any preferred stockholders. As of September 30, 2024, no dividends on common stock had been declared by the Company.

ATM Program: On October 4, 2021, the Company entered into an at-the-market offering program (the "ATM Program") pursuant to which, the Company may offer and sell shares of its common stock having aggregate gross sales proceeds of up to \$150.0 million from time to time. During the three and nine months ended September 30, 2024, the Company did not sell any shares of its common stock under the ATM Program. As of September 30, 2024, the Company has approximately \$113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program.

8. Stock Plan: 2020 Equity Incentive Plan: The 2020 Equity Incentive Plan (the "2020 Plan") was approved by the board of directors on September 24, 2020. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company's officers, employees, directors, and consultants. The number of shares of common stock initially reserved for issuance under the 2020 Plan was 4,406,374, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, in an amount equal to the least of (i) 4,406,374 shares of common stock, (ii) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (iii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2024, the board's compensation committee, as the 2020 Plan administrator, exercised its discretion under clause (ii) to increase the number of shares of common stock reserved for issuance under the 2020 Plan by 2,572,174 shares, effective as of January 1, 2024. As of September 30, 2024, there were 5,329,431 shares available for issuance under the 2020 Plan.

10. PMV Pharmaceuticals, Inc. Notes to Condensed Consolidated Financial Statements (unaudited) (in thousands, except share and per share amounts)

On September 9, 2022, the Company granted 374,899 Restricted Stock Units ("RSUs") to employees pursuant to an employee retention program approved by the board's compensation committee. The RSUs have graded vesting on an annual basis for two years of continuous service, as per the 2020 Plan. As of September 30, 2024, the RSUs were fully vested and common stock was issued upon the settlement of the RSUs. On January 18, 2024, the Company granted 952,665 RSUs to employees VP-level or higher, pursuant to an employee retention program approved by the compensation committee of the Company's board of directors. The RSUs are scheduled to vest on June 30, 2025, based on approximately one and a half years of continuous service, as per the 2020 Plan.

2020 Employee Stock Purchase Plan: The 2020 Employee Stock Purchase Plan (the "2020 ESPP") was approved by the board of directors on September 24, 2020. A total of 400,752 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2021 and each January 1 thereafter, to the lesser of (i) 801,504 shares of common stock, (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (iii) an amount determined by the board of directors or any of its committees no later than the last day of the immediately preceding fiscal year. For 2024, the 2020 ESPP reserved shares were increased under clause (ii) by 514,434 shares, effective as of January 1, 2024. As of September 30, 2024, 275,497 shares are issued or outstanding, and there were 1,136,410 shares available for issuance under the 2020 ESPP.

Stock Options: On July 16, 2024, the Company filed with the Securities and Exchange Commission a Tender Offer Statement on Schedule TO defining the terms and conditions of a one-time voluntary stock option exchange to its employees of certain options to purchase up to an aggregate of 2,820,491 shares of the Company's common stock (the "Option Exchange"). On August 13, 2024, the completion date of the Option Exchange, stock options covering an aggregate of 2,786,691 shares of common stock were tendered by eligible employees, and the Company granted new options at an exercise price of \$1.48, the Company's closing stock price on August 13, 2024, covering an aggregate of 2,786,691 shares of common stock under the 2020 Equity Incentive Plan in exchange for the tendered options. As a result of the Option Exchange, the Company will recognize incremental stock-based compensation expense of \$1,370 over the requisite service period of the new stock options, which is three or four years. The Company will recognize the sum of the incremental stock-based compensation expense and the remaining unrecognized compensation expense for the original awards on the modification date, over the requisite service period of the new stock options. The following table summarizes option activity for the nine-month period ended

product candidates; obtain, maintain, protect, and enforce our intellectual property portfolio; and hire additional personnel. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company that we did not experience as a private company. We expect to continue to incur significant losses for the foreseeable future. 15 Å Our ability to generate product revenue will depend on the successful development, regulatory approval, and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative, or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates. We plan to continue to use third-party service providers, including clinical research organizations, or CROs, and contract manufacturing organization, or CMOs, to carry out our preclinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. We do not currently have a sales force. Components of Results of Operations Revenue To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. Operating Expenses Research and Development Expenses Our research and development expenses consist primarily of costs incurred to conduct research, such as the discovery and development of our product candidates as well as the development of future product candidates. Research and development expenses include personnel costs, including stock-based compensation expense, third-party contractor services, laboratory materials and supplies, and depreciation and maintenance of research equipment. We expense research and development costs as they are incurred. We do not allocate our costs by product candidate or development program, as a significant amount of research and development expenses include compensation costs, materials, supplies, depreciation on and maintenance of research equipment, and the cost of services provided by outside contractors, which are not tracked by product candidate or development program. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. Substantially all of our research and development costs are associated with our lead product candidate, PC14586 (rezatapopt). We initiated a Phase 1/2 clinical trial in October 2020 for our lead product candidate, PC14586. In October 2020, we were granted FDA Fast Track Designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation. In October 2023, we presented our updated Phase 1 clinical data for PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting. We are continuing to dose patients, and have activated over 60% of sites globally across the US, Europe and Asia-Pacific, in the registration, tumor-agnostic PYNNACLE Phase 2 trial of PC14586 in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type (WT). In October 2024, we discontinued enrollment in the Phase 1b combination arm of the PYNNACLE trial evaluating rezatapopt in combination with Merck and Co.â€™s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors harboring a TP53 Y220C mutation. Additionally, we announced that we are collaborating with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study, which is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of rezatapopt monotherapy in combination with azacytidine in patients harboring a TP53 Y220C mutation. We expect that enrollment for this Phase 1b study will begin in the first quarter of 2025. We also expect to provide interim data on the Phase 2 monotherapy registration portion of the PYNNACLE trial by mid-2025. We expect our research and development expenses to increase substantially in absolute dollars in the future as we advance our product candidates into and through clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, clinical data, investment in our clinical program, the ability of any future collaborators to successfully develop our licensed product candidates, competition, manufacturing capability, and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects. 16 Å General and Administrative Expenses General and administrative expenses include personnel costs, expenses for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits, and stock-based compensation. Outside professional services consist of legal, accounting and audit services and other consulting fees. Allocated expenses consist of rent expense related to our office and research and development facilities. We also expect to increase our general and administrative expenses as we advance our product candidates through preclinical research and development, manufacturing, clinical development, and commercialization. Interest Income, Net Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to accretion and amortization of discounts and premiums on marketable securities. Results of Operations Comparison of the Three Months Ended September 30, 2024 and 2023. The following table summarizes our results of operations (in thousands): Å Å Å Three Months Ended September 30, Å Å Å Statement of operations data: Å 2024(Unaudited) Å 2023(Unaudited) Å Change Å Operating expenses: Å Å Å Å Å Å Å Å Research and development Å \$ 16,947 Å \$ 13,586 Å \$ 3,361 Å General and administrative Å 4,941 Å Å 6,042 Å Å (1,101) Å Å Å Å Å Å Å Total operating expenses Å 21,888 Å Å 19,628 Å Å 2,260 Å Å Å Å Å Å Å Loss from operations Å (21,888) Å (19,628) Å Å (2,260) Other income: Å Å Å Å Å Å Interest income, net Å 2,615 Å Å 2,984 Å Å (369) Other income, net Å 121 Å 121 Å 4 Å Å 117 Å Å Å Å Å Total other income Å 2,736 Å Å 2,988 Å Å (252) Å Å Å Å Å Å Loss before provision for income taxes Å (19,152) Å Å (16,640) Å Å (2,512) Provision for income taxes Å 74 Å Å Å Å Å Net loss Å \$ (19,226) Å \$ (16,640) Å \$ (2,586) Å Research and Development Expenses The following table summarizes our research and development expenses incurred during the periods indicated (in thousands): Å Å Å Three Months Ended September 30, Å Å Å Statement of operations data: Å 2024(Unaudited) Å 2023(Unaudited) Å Change Å Research Å \$ 1,743 Å Å 1,920 Å Å \$ (177) Development Å \$ 11,055 Å Å 6,785 Å Å 4,270 Å Personnel related Å 3,140 Å Å 3,381 Å Å (241) Stock-based compensation Å \$ 1,009 Å Å 1,500 Å Å (491) Total Å \$ 16,947 Å Å \$ 13,586 Å Å \$ 3,361 Å Å 17 Å Research and development expenses were \$16.9 million for the three months ended September 30, 2024, compared to \$13.6 million for the three months ended September 30, 2023. The increase of \$3.3 million, compared to the three months ended September 30, 2023, was primarily due to the following: â€¢\$4.1 million increase in research and development expenses associated with advancing our lead product candidate, PC14586, through the Phase 1/2 clinical trial; and â€¢\$0.7 million decrease in expenses for personnel related costs and stock-based compensation, primarily driven by decreased headcount from our reduction in force initiated in January 2024. General and Administrative Expenses General and administrative expenses were \$4.9 million for the three months ended September 30, 2024, compared to \$6.0 million for the three months ended September 30, 2023. The decrease of \$1.1 million, compared to the three months ended September 30, 2023, was primarily due to following: â€¢\$0.9 million decrease in personnel expenses driven by a decrease in headcount and \$0.2 million decrease in director and officer insurance fees. Interest Income, Net Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to accretion and amortization of discounts and premiums on marketable securities. Interest income, net was \$2.6 million for the three months ended September 30, 2024. The decrease of \$0.4 million compared to the three months ended September 30, 2023, is driven by less cash and investments in marketable securities and U.S. treasuries during the three months ended September 30, 2024. Comparison of the Nine Months Ended September 30, 2024 and 2023. The following table summarizes our results of operations (in thousands): Å Å Å Nine Months Ended September 30, Å Å Å Statement of operations data: Å 2024(Unaudited) Å 2023(Unaudited) Å Change Å Operating expenses: Å Å Å Å Å Å Å Å Research and development Å \$ 44,760 Å Å \$ 42,503 Å Å \$ 2,257 Å General and administrative Å 15,520 Å Å 18,727 Å Å (3,207) Å Å Å Å Å Å Å Total operating expenses Å 60,280 Å Å 61,230 Å Å (950) Å Å Å Å Å Å Å Loss from operations Å (60,280) Å Å (61,230) Å Å 950 Å Other income: Å Å Å Å Å Å Interest income, net Å 8,368 Å Å 8,005 Å Å 363 Å Other income, net Å 103 Å Å 24 Å Å 79 Å Å Å Å Å Å Å Total other income Å 8,471 Å Å 8,029 Å Å 442 Å Å Å Å Å Å Loss before provision for income taxes Å (51,809) Å Å (53,201) Å Å 1,392 Å (Benefit) provision for income taxes Å (16,100) Å Å 3 Å Å (16,103) Å Å Å Å Å Net loss Å \$ (35,709) Å \$ (53,204) Å \$ 17,495 Å Å 18 Å Research and Development Expenses The following table summarizes our research and development expenses incurred during the periods indicated (in thousands): Å Å Å Nine Months Ended September 30, Å Å Å Statement of operations data: Å 2024(Unaudited) Å 2023(Unaudited) Å Change Å Research Å \$ 4,370 Å Å 5,366 Å Å \$ (996) Development Å 26,583 Å Å 23,074 Å Å 3,509 Å Personnel related Å 10,563 Å Å 9,924 Å Å 639 Å Stock-based compensation Å 3,244 Å Å 4,139 Å Å (895) Total Å \$ 44,760 Å Å \$ 42,503 Å Å \$ 2,257 Å Research and development expenses were \$44.8 million for the nine months ended September 30, 2024, compared to \$42.5 million for the nine months ended September 30, 2023. The increase of \$2.3 million, compared to the nine months ended September 30, 2023, was primarily due to the following: â€¢\$2.5 million increase in research and development expenses, largely driven by increased contractual research organization costs; offset by â€¢\$0.2 million decrease in expenses for personnel related costs and stock-based compensation as a result of reduced headcount from our reduction in force initiated in January 2024. General and Administrative Expenses General and administrative expenses were \$15.5 million for the nine months ended September 30, 2024, compared to \$18.7 million for the nine months ended September 30, 2023. The decrease of \$3.2 million, compared to the nine months ended September 30, 2023, was primarily due to following: â€¢\$1.8 million decrease in personnel expenses driven by a decrease in headcount, \$1.1 million decrease in facility and equipment expenses due to expiration of three leases, and \$0.5 million decrease in director and officer insurance fees and legal expenses; offset by â€¢\$0.2 million increase in finance and legal support expenses. Interest Income, Net Interest income, net primarily consists of interest income from our interest-bearing cash, cash equivalents and marketable securities and interest costs related to accretion and amortization of discounts and premiums on marketable securities. Interest income, net was \$8.4 million for the nine months ended September 30, 2024. The increase of \$0.4 million compared to the nine months ended September 30, 2023, is driven by increased interest rates from cash and investments in marketable securities and U.S. treasuries during the nine months ended September 30, 2024. Income Tax Benefit As of September 30, 2024, the Company received \$16.2 million of cash for the NOL and R&D tax credit sales related to the tax years ended December 31, 2015 to 2022. The sale of the NOLs and R&D tax credits have been recorded as an income tax benefit within the condensed consolidated statement of operations. 19 Å Liquidity and Capital Resources Our financial condition is summarized as follows (in thousands): Å Å Å As of September 30, Å Å Å As of December 31, Å Å Å 2024 Å 2023 Å Change Å Financial assets: Å Å Å Å Å Å Å Å Cash and cash equivalents Å \$ 48,810 Å Å \$ 37,706 Å Å \$ 11,104 Å Marketable securities â€¢ current Å 134,031 Å Å 165,351 Å Å (31,320) Marketable securities â€¢ noncurrent Å 15,096 Å Å 25,505 Å Å (10,409) Total financial assets Å \$ 197,937 Å Å \$ 228,562 Å Å \$ (30,625) Å Å Å Å Å Working capital: Å Å Å Å Å Å Current assets Å \$ 189,620 Å Å \$ 207,409 Å Å \$ (17,789) Current liabilities Å (13,563) Å Å (14,029) Å Å 466 Å Total working capital Å \$ 176,057 Å Å \$ 193,380 Å Å \$ (17,323) Å Sources of Liquidity Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all. As of September 30, 2024, we had cash, cash equivalents, and marketable securities of \$197.9 million and an accumulated deficit of \$345.7 million. On October 4, 2021, we filed a shelf registration statement on Form S-3, as amended, (File No. 333-260012) with the SEC, or the Prior Shelf Registration Statement, which registered the offering, issuance, and sale of up to \$200 million of various equity and debt securities and up to \$150 million of common stock pursuant to an at-the-market equity offering program with Jefferies LLC, dated October 4, 2021, or the ATM Program. The Prior Shelf Registration Statement expired on October 4, 2024 and no shares of our common stock were able to be sold pursuant to the ATM Program following such date. We expect to file a new shelf registration statement on Form S-3 in order to, amongst other things, issue and sell common stock pursuant to the ATM Program. During the three and nine months ended September 30, 2024, we did not sell any shares of its common stock under the ATM Program. As of September 30, 2024, we have approximately \$113.8 million remaining in gross proceeds available for future issuances of common stock under

the ATM Program. Contractual Obligations and Commitments We enter into contracts in the normal course of business with CROs and other vendors to assist in the performance of our research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments. In January 2021, we signed a lease for 50,581 square feet of office and laboratory space at One Research Way in Princeton, New Jersey. That lease term extends through 2032 and has a five-year extension option. Amounts related to future lease payments as of September 30, 2024, totaled \$13.9 million, with \$1.9 million to be paid within the next 12 months. In August 2024, the Company entered into a Lease Termination Agreement with BMR-One Research Way LLC, in connection with the termination of the lease at One Research Way in Princeton, New Jersey. Pursuant to the Termination Agreement, the Company and the Landlord agreed to terminate the lease, contingent on the sale of the property by the Landlord to a prospective new buyer. The sale to the new buyer was completed on October 1, 2024 and the lease was terminated on such date. In September 2024, we signed two subleases, one for 14,201 square feet of office space at 400 Alexander Park Drive, Suite 301, in Princeton, New Jersey, to be used as our new headquarters (â€œ400 Alexander Subleaseâ€), and the other for 3,025 square feet of office and laboratory space at 311 Pennington Rocky Hill in Hopewell, New Jersey, to be used for our new laboratory space (â€œ311 Pennington Subleaseâ€). The 400 Alexander Sublease term extends until February 28, 2027, and the 311 Pennington Sublease term extends until December 2029 and has a three-year extension option. Amounts related to future lease payments for 311 Pennington Sublease as of September 30, 2024, totaled \$0.8 million with \$0.1 million to be paid within the next 12 months. Amounts related to future lease payments for 400 Alexander Sublease as of October 1, 2024 totaled \$0.8 million with \$0.3 million to be paid within the next 12 months. 20 **Plan of Operation and Future Funding Requirements** We use our capital resources primarily to fund operating expenses, mainly research and development expenditures. On January 18, 2024, we announced a restructuring plan involving the reduction of our workforce by approximately 30% of our employees. All of the costs under the restructuring plan were incurred during the nine months ended September 30, 2024. We undertook these steps in order to streamline operations, reduce costs and preserve capital as we advance our lead candidate, PC14586, into late-stage development. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval and commercialize our current product candidates or any future product candidates, if at all. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. Due to our significant research and development expenditures, we have generated substantial operating losses in each period since inception. We have incurred an accumulated deficit of \$345.7 million through September 30, 2024. We expect to incur substantial additional losses in the future as we expand our research and development activities. For the nine months ended September 30, 2024 and 2023, our cash operating expenditures were \$34.6 million and \$43.6 million, respectively. Based on our research and development plans, we expect that our cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund our operations to the end of 2026. We have based this estimate on assumptions that may prove to be wrong, however, and we could use our capital resources sooner than we expect. The timing and amount of our operating expenditures will depend largely on: â€¢the timing and progress of preclinical and clinical development activities; â€¢the number and scope of preclinical and clinical programs we decide to pursue; â€¢the timing and amount of milestone payments we may receive under any future collaboration agreements; â€¢our ability to maintain future licenses and research and development programs and to establish new collaboration and/or in-licensing arrangements; â€¢the costs involved in prosecuting and enforcing patent and other intellectual property claims; â€¢the cost and timing of regulatory approvals; â€¢the costs involved in finalizing our announced reduction in force and related reorganization; and â€¢our efforts to manage our office and laboratory headquarters, enhance operational systems and hire additional personnel to support development of our product candidates and satisfy our obligations as a public company. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to fund our operations and capital funding needs through equity and/or debt financing. We may also consider entering into collaboration arrangements or selectively partnering for clinical development and commercialization. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations or our ability to incur additional indebtedness or pay dividends, among other items. If we raise additional funds through governmental funding, collaborations, strategic partnerships and alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially and adversely affect our business, financial condition, results of operations and prospects. 21 **Cash Flows** The following table summarizes our cash flows for the period indicated (in thousands):

Period	Operating Activities	Investing Activities	Financing Activities	Net Cash Flow
Nine Months Ended September 30, 2024 (Unaudited)	\$ (34,621)	\$ (43,572)	\$ (141)	\$ (78,234)
Nine Months Ended September 30, 2023 (Unaudited)	\$ (35,289)	\$ (35,289)	\$ (140)	\$ (70,718)
Net Increase (Decrease) in Cash and Cash Equivalents	\$ 11,104	\$ (56,240)	\$ (141)	\$ (43,075)

22 *We* believe that the accounting policies described below involve a high degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our financial condition and results of our operations. During the nine-month period ended September 30, 2024, there were no material changes to our critical accounting policies from those described in our audited condensed consolidated financial statements for the year ended December 31, 2023, included in our Annual Report on Form 10-K filed with the SEC on February 29, 2024, except as noted below. **Research and Development Costs, Accrued Research and Development Costs and Related Prepaid Expenses** Research and development costs are expensed as incurred. Research and development expenses consist principally of personnel costs, including salaries, stock-based compensation and benefits for employees, third-party license fees and other operational costs related to our research and development activities, including sourcing of raw materials and manufacturing of our product candidates, allocated facility-related expenses and external costs of outside vendors, and other direct and indirect costs. Non-refundable research and development advance payments are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or services are performed. As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include fees paid to: â€¢vendors, including research laboratories, in connection with preclinical development activities; â€¢CROs and investigative sites in connection with preclinical studies and clinical trials; and â€¢CMOs in connection with drug substance and drug product formulation of preclinical studies and clinical trial materials. We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that supply, conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. **Recent Accounting Pronouncements** For a description of recent accounting pronouncements, see Note 2 of the notes to our unaudited condensed consolidated financial statements for the nine months ended September 30, 2024 included elsewhere in this Quarterly Report on Form 10-Q. **Item 3. Quantitative and Qualitative Disclosures About Market Risk** We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks. We had cash, cash equivalents, and marketable securities of \$197.9 million and restricted cash of \$0.8 million as of September 30, 2024. The Companyâ€™s cash equivalents consist of interest-bearing U.S. treasury securities, money market funds, and corporate debt securities. Our exposure due to changes in interest rates is not material due to the nature and amount of our money-market funds and marketable securities. **Item 4. Controls and Procedures** We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Securities Exchange Act of 1934, as amended, reports is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms and that such information is accumulated and communicated to our

management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We carry out a variety of ongoing procedures, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, to evaluate the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2024. There have not been any changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 24. PART II^o"OTHER INFORMATION Item 1. Legal Proceedings. We are not currently involved in any litigation or legal proceedings that, in management's opinion, are likely to have any material adverse effect on the Company. Item 1A. Risk Factors. There have been no material changes to the Company's risk factors as set forth in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 29, 2024, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on May 9, 2024. You should carefully review and consider the information regarding certain factors which could materially affect our business, financial condition or future results set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 29, 2024, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on May 9, 2024. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. (a) Unregistered Sales of Equity Securities None. (b) Use of Proceeds Our registration statement on Form S-1 (File No. 333-248627) relating to the IPO was declared effective by the SEC. The IPO closed on September 25, 2020 at which time we sold 13,529,750 shares of common stock (including the exercise in full by the underwriters of their option to purchase an additional 1,764,750 shares of common stock) at a public offering price of \$18.00 per share. We received net proceeds from the IPO of approximately \$223.2 million, after deducting the underwriting discounts and commissions of approximately \$17.0 million and estimated offering related expenses of approximately \$3.3 million. No offering expenses were paid or payable, directly, or indirectly, to our directors, officers, or persons owning 10% or more of any class of equity securities or to our affiliates. Goldman Sachs & Co. LLC, BofA Securities, Cowen, and Evercore ISI acted as joint book-running managers for the offering. There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on September 24, 2020. On October 4, 2021, we filed a shelf registration statement on Form S-3, as amended (File No. 333-260012), or the Prior Shelf Registration Statement, which was subsequently declared effective by the SEC on April 28, 2022. The Prior Shelf Registration Statement consisted of (i) a base prospectus pursuant to which we may offer and sell, from time to time, up to \$200 million of shares of our common stock, shares of our preferred stock, various series of debt securities and warrants to purchase any of such securities in one or more registered offerings, and (ii) a prospectus supplement pursuant to which we may offer and sell, from time to time, up to \$150 million of shares of common stock in "at-the-market" offerings. The Prior Shelf Registration Statement expired on October 4, 2024 and no shares of our common stock were able to be sold pursuant to the ATM Program following such date. We expect to file a new shelf registration statement on Form S-3 in order to, among other things, issue and sell common stock pursuant to the ATM Program. During the three and nine months ended September 30, 2024, the Company did not sell any shares of its common stock under the ATM Program. As of September 30, 2024, we have approximately \$113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program. There has been no material change in the planned use of proceeds as described in the Prior Shelf Registration Statement. None of the offering expenses were paid or payable, directly, or indirectly, to our directors, officers, or persons owning 10% or more of any class of equity securities or to our affiliates. (c) Issuer Purchases of Equity Securities. None. Item 3. Defaults Upon Senior Securities. None. 25. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. Not applicable. 26. Item 6. Exhibits. A ExhibitNumber A Description Form File No. Number Filing Date A A A A A 3.1 A Amended and Restated Certificate of Incorporation of the Registrant 8-K 001-39539 3.1 September 29, 2020 A A A A A 3.2 A Amended and Restated Bylaws of the Registrant 10-Q 001-39539 3.2 May 10, 2023 A A A A A 10.1 A Lease Termination Agreement, dated August 5, 2024, by and between BMR-One Research Way LLC and PMV Pharmaceuticals, Inc. 8-K 001-39539 10.1 August 8, 2024 A A A A A 31.1+ A Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A A A A A A A A 31.2+ A Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A A A A A A A A 32.1+ A Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A A A A A A A A 32.2+ A Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A A A A A A A A 101.INS Inline XBRL Instance Document A A A A A A A A A 101.SCH A Inline XBRL Taxonomy Extension Schema Document A A A A A A A A A 104 A Cover Page Interactive Data File (embedded within the Inline XBRL document) A A A A A A The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing. + Filed herewith. 27. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized. A A A PMV Pharmaceuticals, Inc. A A A Date: November 7, 2024 A By: /s/ David H. Mack A A David H. Mack, Ph.D. A A President, Chief Executive Officer, and Director A A A (Principal Executive Officer) A A A A A PMV Pharmaceuticals, Inc. A A A Date: November 7, 2024 A By: /s/ Michael Carulli A A Michael Carulli A A Chief Financial Officer A A A (Principal Financial and Principal Accounting Officer) A 28 EX-31.1 A Exhibit 31.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David H. Mack, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024, of PMV Pharmaceuticals, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 7, 2024 By: /s/ David H. Mack David H. Mack, Ph.D. President, Chief Executive Officer, and Director(Principal Executive Officer) A A EX-31.2 A Exhibit 31.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Carulli, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024, of PMV Pharmaceuticals, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. A Date: November 7, 2024 By: /s/ Michael Carulli Michael Carulli Chief Financial Officer(Principal Financial and Principal Accounting Officer) A A EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2024, of PMV Pharmaceuticals, Inc. (the "Company"), as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. A§ 1350, as adopted pursuant to A§ 906 of the Sarbanes-Oxley Act of 2002, that: (1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. A Date: November 7, 2024 By: /s/ David H. Mack David H. Mack, Ph.D. President, Chief Executive Officer, and Director(Principal Executive Officer) A A EX-32.2 A Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2024, of PMV Pharmaceuticals, Inc. (the "Company") as filed with the Securities and Exchange Commission on the date hereof (the

â€œReportâ€), I certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that: (1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. A Date: November 7, 2024 By: /s/ Michael Carulli Michael Carulli Chief Financial Officer(Principal Financial and Principal Accounting Officer) A A